Brief: IRLAB: Top-Line Results From Phase IIb Trial Of Mesdopetam In Parkinson's Disease

IRLAB Therapeutics AB

18/01/2023 07:24

Jan 18 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * ANNOUNCED ON TUESDAY THE TOP-LINE RESULTS FROM THE PHASE
IIB
STUDY OF MESDOPETAM IN PEOPLE WITH PARKINSON'S DISEASE
LEVODOPA-INDUCED DYSKINESIAS (PD-LIDS)
    * PRIMARY ENDPOINT, CHANGE IN DAILY HOURS OF ON-TIME WITHOUT
TROUBLESOME DYSKINESIA, AS ASSESSED WITH PATIENT DIARIES, DID
NOT REACH STATISTICAL SIGNIFICANCE BY MESDOPETAM COMPARED TO
PLACEBO
    * MESDOPETAM DEMONSTRATED SIGNIFICANT ANTI-DYSKINETIC
EFFECTS AS
MEASURED BY A SECONDARY ENDPOINT UDYSRS
    * MESDOPETAM DISPLAYED AN ADVERSE EVENT AND TOLERABILITY
PROFILE
SIMILAR TO PLACEBO

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN3phqfd
 Further company coverage:  IRLABa.ST  
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))